Background
==========

The diagnostic and therapeutic advances of recent years have only marginally reduced mortality associated with infective endocarditis (IE). Thus, a 30% mortality rate was reported after the introduction of antimicrobial therapy \[[@B1]\] but 50 years later, despite the introduction of new antimicrobial agents and advances in surgical therapy, and even though some recent publications found mortality rates lower than 20%\[[@B2],[@B3]\], it remains around 20-40% in most series \[[@B4],[@B5]\].

During the past few years, several published epidemiological studies have identified a number of prognostic factors related to higher mortality, such as advanced age \[[@B6],[@B7]\], female gender \[[@B6]\], prosthetic valve endocarditis \[[@B6],[@B7]\], *Staphylococcus aureus*aetiology \[[@B6]-[@B10]\], comorbidity \[[@B6],[@B9]\], analytical data (leucocytosis \[[@B11]\], hypoalbuminemia \[[@B11]\], C-reactive protein values \[[@B12]\] and elevated ERS \[[@B7]\]), and the development of various complications (heart failure \[[@B6]-[@B9],[@B12],[@B13]\], cerebral embolism \[[@B7],[@B10],[@B12]\] renal insufficiency \[[@B6]\], septic shock \[[@B10]\] and paravalvular extension \[[@B7]\]). However, studies investigating prognostic factors for IE frequently have methodological flaws since they are based on short retrospective series, the experience of a single hospital, or use non-uniform diagnostic criteria. Moreover, many of these studies are performed in referral centers, where the most complicated cases are usually treated \[[@B14]\]. More accurate information may be obtained from prospective multicenter studies, in which it is possible to include a large number of cases based on strict diagnostic criteria. Knowledge of potentially modifiable risk factors should help to identify those patients who might benefit from more aggressive diagnostic and/or therapeutic procedures \[[@B15]\]. Our objective was to investigate factors associated with a worse prognosis in a multicenter cohort of left-sided IE patients.

Methods
=======

Study design and patients
-------------------------

All patients diagnosed of IE in seven hospitals in Andalusia (South of Spain) were consecutively registered in a uniform database from January 1984 throughout December 2006. Five are tertiary referral hospitals for cardiac surgery and 2 are community hospitals; the latter transferred patients evaluated as being at higher risk for mortality to the referral centres. All cases of left-sided IE defined according to Duke criteria \[[@B16]\] with later modifications \[[@B17]\] for definite and possible IE were included. Patients registered before 1994 were retrospectively evaluated for diagnostic criteria. In the case of relapses, only the first episode was included. Cases with insufficient follow-up (not longer than one month) were excluded.

Variables and definitions
-------------------------

Data were recorded prospectively by members of the Infectious Diseases services or units in the participating centres using a structured questionnaire and introduced into a common database. The cases were detected from routine review of microbiology, echocardiography and surgery reports. The primary outcome measure was overall mortality during hospitalisation (in-hospital death). All cases with no signs of infection and a negative post-antimicrobial treatment culture were considered cured. Relapses, defined as an IE episode occurring within 6 months of a previous one and caused by the same microorganism, were also recorded. Recurrence was defined as a new IE episode in the same patient and related to a different microorganism. The following independent variables were recorded: age, sex, health care-associated acquisition, type and severity of underlying comorbidity evaluated according to the age-adjusted Charlson index \[[@B18]\], duration of symptoms before diagnosis, septic shock, heart failure, embolism, neurologic manifestations, acute renal failure, echocardiographic findings (vegetations and size, abscess, prosthetic dehiscence and valvular dysfunction), microbiologic data (microorganisms isolated from blood cultures and/or valve tissues, and serologic tests), and treatment (medical and surgical). For analysis purposes, the study period was arbitrary divided in two: 1984 - 1995 and 1996 - 2006.

The additive euroSCORE index \[[@B19]\] were calculated for operative risk evaluation in every patient. Predisposing valvulopathy was defined as any previous valvular heart lesion that predispose to IE. Prosthetic endocarditis was considered as early if it occurred within one year of valve implantation and late otherwise. Heart failure was defined according to Framingham\'s criteria \[[@B20]\] and was evaluated at admission and during evolution. Septic shock was defined according to standard criteria \[[@B21]\]. Perivalvular extension was defined as the presence of an abscess and/or fistula and/or pseudoaneurism diagnosed by echocardiogram, in surgery or at autopsy. A major symptomatic embolism was considered if the central nervous system, spleen or extremities were affected. Neurologic manifestations were considered only in patients with clinical manifestations related to encephalopathy, meningitis, cerebral infarct or a haemorrhage, and demonstrated by cerebrospinal fluid analysis, radiological test or at autopsy. Severe renal insufficiency was defined as a serum creatinin level \>2.5 mg/dl. Left-sided IE were considered nosocomially acquired using previously published criteria \[[@B22]\]. After 1994 transesophagic echocardiography (TEE) was performed in cases with a high clinical probability of IE when transthoracic echochardiography (TTE) was not diagnostic, and routinely in prosthetic IE or when cardiac complications were suspected.

This study was approved by ethical and research committees of all participating hospitals.

Statistical analysis
--------------------

The association of the different variables with the outcome was firstly analysed by univariate analysis. Continuous variables were expressed like mean ± standard deviation or like median and interquartile rank in case of abnormal distribution and were analysed using the Student\'s T test or the Mann-Whitney U test as appropriate. Categorical variables were expressed like absolute numbers and proportion of cases and were compared using the chi-squared or Fisher\'s test when appropriate. Relative risks with 95% confidence interval for mortality were calculated. Then, multivariate analysis was performed using logistic regression. The multivariate model was built including all variables with a significant association in univariate analysis (p \< 0.05) and those considered potentially clinically relevant; modification effects between variables were also studied. The selection of variables was performed using a stepwise backward procedure. All statistical studies were performed using SPSS software (v12.0, Chicago, IL, USA).

Results
=======

General features of the cohort
------------------------------

Seven hundred and five case-patients of left-sided IE were included in the study. Only other 8 patients were excluded because insufficient evolution data. Among included cases, 624 (88%) were considered as definite and 81 (12%) as possible IE. Mean (± SD) post-hospitalisation follow-up was 15.75 ± 25.05 months (range: 1-192). The median age of the patients was 56 years (interquartile rank from 41 to 68 years), only 5 patient were ≤ 15 years old. Four hundred and eighty six (69%) patients were male. Native valves were affected in 534 (76%) cases. Of 171 patients (24%) with prosthetic IE, 69 were considered early and 102 late. The aortic valve was affected in 320 (45%) cases, the mitral valve in 299 (42%), and both valves were affected in 86 (11%) patients. Globally, 488 (69%) had a predisposing valvulopathy for IE and 57 (8%) had suffered at least one previous episode of IE. The mean (± SD) age-adjusted Charlson index was 1.84 ± 2.27 (range: 0-10), and the most frequent underlying diseases were: diabetes mellitus (35 patients, 5%), non-valvular heart diseases (32 patients, 5%), chronic liver diseases (32 patients 5%); neoplasia (28 patients, 4%); chronic renal insufficiency (24 patients, 3%); and chronic lung disease (16 patients, 2%). Forty-six patients (7%) were intravenous drug abusers.

Aetiology was established by isolating the causative microorganism from blood culture in 598 (85%) patients, a surgically-explanted valve culture in 70 (10%) and by serologic test in 35 (5%). *Streptococcus viridans*group was the most frequent microorganism isolated, followed by *Staphylococcus aureus*, coagulase-negativestaphylococci and *Enterococcus spp*. (table [1](#T1){ref-type="table"}). In 71 cases (10%), aetiology was unknown, because all microbiological studies were negatives.

###### 

Microbiologic aetiology by IE type in 705 patients with left-sided infective endocarditis.

  --------------------------------------------------------------------------------------
  Microorganism                         Native      Early\       Late\        Total
                                                    Prosthetic   Prosthetic   
  ------------------------------------- ----------- ------------ ------------ ----------
  *Streptococci*                                                              

                                                                              

   *Streptococcus viridans*group        132 (25)    3 (4)        21 (21)      156 (22)

                                                                              

   *Enterococcus spp*                   60 (11)     6 (9)        12 (12)      78 (11)

                                                                              

   *Streptococcus bovis*                18 (3)      0            1 (1)        19 (3)

                                                                              

   *Streptococcus agalactiae*           12 (2)      0            3 (3)        15 (2)

                                                                              

   *Others*                             21 (4)      0            3 (3)        24 (3)

                                                                              

  *Staphylococci*                                                             

                                                                              

   *Staphylococcus aureus*              106 (21)    11 (16)      12 (14)      137 (19)

                                                                              

   Coagulase-negative *Staphylococci*   45 (8)      34 (50)      23 (23)      102 (15)

                                                                              

  Gramnegative bacilli                  14 (3)      1 (2)        1 (1)        16 (2)

                                                                              

  HACEK Group                           5 (1)       0            4 (4)        9 (1)

                                                                              

  *Brucella spp*                        12 (2)      0            0            12 (2)

                                                                              

  *Coxiella burnetii*                   12 (2)      0            6 (6)        18 (3)

                                                                              

  Fungi                                 5 (1)       3 (4)        1 (1)        9 (1)

                                                                              

  *Other*                               12 (2)      4 (6)        4 (4)        20 (3)

                                                                              

  Polymicrobial                         19 (4)      0            0            19 (3)

                                                                              

  Unknown                               53 (10)     7 (10)       11 (11)      71 (10)

                                                                              

  Total                                 534 (100)   69 (100)     102 (100)    705
  --------------------------------------------------------------------------------------

Data are expressed as number of cases (%).

Echocardiography was performed on 698 patients: TTE alone on 409 (58%), TEE alone on 16 (2%) and both TTE and TEE on 273 patients (39%). In 7 patients, no echocardiographic study was performed because endocarditis was not suspected until surgery or necropsy. Overall, TTE was diagnostic in 448 of 682 patients (66%) in which it was performed, and TEE in 251 of 289 (87%). In 156 patients where a TTE study was not diagnostic, a TEE study obtained a defined diagnosis of IE in 122 (78.2%).

Many patients developed complications: 282 (40%) had cardiac failure, 194 (27%) presented neurologic manifestations, 280 (40%) had systemic embolisms (in 147 cases, the central nervous system was affected), 190 (27%) developed acute renal insufficiency, 86 (12.2%) septic shock, and 87 (13%) perivalvular extension (perivalvular abscess, 70; fistula 15; and pseudoaneurism 2).

Valvular surgery was performed in 269 patients (38%). The most frequent indications for surgery were severe heart failure (in 171 patients, 63.5%), followed by valve dysfunction (37 patients, 13.7%), persistent sepsis (21 patients, 7.8%), and perivalvular extension (8 patients, 2.9%). There were several indications for surgery in 27 patients (10.0%). Fifty and three (7.5%) was not operated because of critical situation and high risk intervention.

Prognosis
---------

Two hundred and eight patients died during their hospital stay (mortality rate, 29.5%). Relapses occurred in 17 patients (2.4%), and the 480 remaining cases (68%) were considered cured. Principal causes of death was: heart failure in 44 patients (21.5%) sepsis in 28 (13.4%) neurologic complications in 22 (10.5%), and by several of these complications in 71(34.1%).

The variables significantly associated with increased mortality in univariate analysis were age, nosocomial acquisition, severity of underlying disease, chronic liver disease, prosthetic valve endocarditis, early prosthetic valve endocarditis, *S. aureus*, *Streptococcus agalactiae*and fungal aetiology, lesser duration of symptoms before diagnosis, development of septic shock, progressive or refractory heart failure, acute renal insufficiency, the presence of cardiac abscess or fistula, and non performed surgery although indicated because of high associated risk (tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Conversely, *Streptococcus viridans*group aetiology was associated with lower mortality rates. The final multivariate model is shown in table [4](#T4){ref-type="table"}; the p value of the Hosmer-Lemeshow goodness-of-fit test for the final model was 0.514.

###### 

Univariate analysis of in-hospital-mortality: patient characteristics and etiology.

  --------------------------------------------------------------------------------------------------------
  *Variable*                                        Alive\       Deaths\      RR     95% CI      *p*
                                                    N = 497      N = 208                         
  ------------------------------------ ------------ ------------ ------------ ------ ----------- ---------
  Age (years)                          Mean ± SD    51.6 ± 17    58.8 ± 16    \-     \-          \<0.001

                                                                                                 

  Gender                               Male         345 (71)     141 (29)     1.07   0.76-1.52   0.367

                                       Female       152 (69.4)   67 (30.6)                       

                                                                                                 

  Period                               1984-1995    196 (74.5)   67 (25.5)    1.25   0.97-1.60   0.070

                                       1996-2006    301 (68.1)   141 (31.9)                      

                                                                                                 

  Hospital                             Tertiary     451 (69.3)   200(30.7)    2.07   1.08-3.96   0.008

                                       Community    46 (85.2)    8 (14.8)                        

                                                                                                 

  Nosocomial                           Yes          55 (53.4)    48 (46.6)    1.75   1.37-2.24   \<0.001

                                       No           442 (73.4)   160 (26.6)                      

                                                                                                 

  Comorbidity                          Yes          259 (64.4)   143 (35.6)   1.65   1.28-2.13   \<0.001

                                       No           238 (78.8)   65 (21.5)                       

                                                                                                 

  Charlson\'s index                    Mean ± SD    1.56 ±       2,50 ±                          \<0.001

                                                    2.15         2.42                            

                                                                                                 

  Diabetes mellitus                    Yes          24 (68.8)    11 (31.4)    1.06   0.64-1.76   0.464

                                       No           473 (70.6)   197 (29.4)                      

                                                                                                 

  Chronic renal insufficiency          Yes          14 (58.3)    10 (41.7)    1.43   0.88-2.33   0.184

                                       No           483 (70.9)   198 (29.1)                      

                                                                                                 

  Chronic liver                        Yes          17 (53.1)    15 (46.9)    1.63   1.10-2.40   0.027

  Disease                              No           480 (71,3)   193 (28,7)                      

                                                                                                 

  Valve involved                       Aortic       223 (71.9)   118 (29.3)   1.02   0.81-1.28   0.456

                                       Mitral       274 (69.3)   90 (29.1)                       

                                                                                                 

  \>1 valve involved                   Yes          49 (64.5)    27 (35.5)    1.23   0.89-1.71   0.223

                                       No           448 (71,2)   181 (28,8)                      

                                                                                                 

  Valve type                           Prosthetic   104 (60.8)   67 (39.2)    1.48   1.17-1.87   0.001

                                       Native       393 (73.6)   141 (26.4)                      

                                                                                                 

  Prosthetic type                      Early        33 (47.8)    36 (52.2)    1.93   1.48-2.50   \<0.001

                                       Late         464 (73)     172 (27)                        

                                                                                                 

  *S. aureus*                          Yes          70 (51.1)    67 (48.7)    1.96   1.57-2.46   \<0.001

                                       No           427 (75.2)   141 (24.8)                      

                                                                                                 

  *S. viridans*group                   Yes          140 (89.7)   16 (10.3)    0.29   0.18-0.47   \<0.001

                                       No           357 (65)     192 (35)                        

                                                                                                 

  Coagulase-negative *Staphylococci*   Yes          64 (62.7)    38 (37.3)    1.32   0.99-1.75   0.040

                                       No           433 (71.8)   170 (28.2)                      

                                                                                                 

  *Enterococcus spp*.                  Yes          52 (66.7)    26 (33.3)    1.14   0.1-1.60    0.254

                                       No           445 (71)     182 (29)                        

                                                                                                 

  *S. agalactiae*                      Yes          7 (46.7)     8 (53.3)     1.84   1.12-2.99   0.044

                                       No           490 (71)     200 (29)                        

                                                                                                 

  Fungal                               Yes          2 (22.2)     7 (77.8)     2.69   1.86-3.89   0.004

                                       No           495 (71.1)   301 (28.9)                      
  --------------------------------------------------------------------------------------------------------

Data are expressed as number of cases (%) except when indicated.

###### 

Univariate analysis of in-hospital-mortality: echocardiographic characteristics, complications and treatment.

  ---------------------------------------------------------------------------------------------------------
  Variable                                      Alive N = 497   Deaths\        RR     95% CI      *P*
                                                                N = 208                           
  --------------------------------- ----------- --------------- -------------- ------ ----------- ---------
  Duration of symptoms (days)       Mean ± SD   40.5 ± 84       20.3 ± 27.4                       \<0.001

                                                                                                  

  Septic shock                      Yes         24 (27.9)       62 (72.1)      3.05   2.51-       \<0.001

                                    No          473 (76.4)      146 (23.6)            3.70        

                                                                                                  

  Severe heart failure              Yes         101 (57.1)      76 (42.9)      1.75   1.59-       \<0.001

  (Admission)                       No          397 (75,1)      131 (24,9)            3.25        

                                                                                                  

  Severe heart failure              Yes         150 (53.2)      132 (46.8)     2.60   2.05-       \<0.001

  (Evolution)                       No          347 (82)        76 (18)               3.31        

                                                                                                  

  Renal insufficiency               Yes         99 (52.1)       91 (47.9)      2.15   1.79-       \<0.001

                                    No          397 (77.8)      113 (22.2)            2.69        

                                                                                                  

  Neurologic                        Yes         113 (57.9)      82 (42.1)      1.70   1.36-       \<0.001

  manifestations                    No          384 (75.3)      126 (24.7)            2.12        

                                                                                                  

  Perivalvular Extension            Yes         44 (51.2)       42 (48.8)      1.82   1.41-2.34   \<0.001

                                    No          453 (73.2)      166 (26.8)                        

                                                                                                  

  Vegetations in echocardiography   Present     362 (68.8)      164 (31.2)     1.29   0.95-       0.075

                                    Absent      133 (75.4)      44 (24.6)             1.68        

                                                                                                  

  Vegetations \> 20 mm\*            Yes         35 (63.6)       20 (36.4)      1.40   0.96-       0.070

                                    No          402 (74)        141 (26)              2.04        

                                                                                                  

  Additive euro SCORE               Mean ± SD   7.86 ± 3.65     12.39 ± 3.07                      \<0.001

                                                                                                  

  Surgical treatment                Yes         180 (67.2)      88 (32.8)      1.19   0.95-       0.07

                                    No          317 (72.5)      120 (27.5)            1.50        

                                                                                                  

  Not performed surgery¶            Yes         7 (13.2)        46 (86.8)      19,8   8.80-       \<0.001

                                    No          490 (75.2)      162(24.8)      7      44.89       
  ---------------------------------------------------------------------------------------------------------

Data are expressed as number of cases (%) except when indicated.

\* Size of vegetations measured in 598 patients. ¶Surgery indicated but not performed

###### 

Multivariate analysis of prognostic factors of in-hospital mortality.

  Variable                           β        OR     95% CI      *P*
  ---------------------------------- -------- ------ ----------- ---------
  Charlson comorbidity score         0.217    1.24   1.14-1.35   \<0.001
                                                                 
  Prosthetic endocarditis            0.688    1.99   1.26-3.14   0.003
                                                                 
  *S. aureus*aetiology               0.760    2.13   1.30-3.50   0.002
                                                                 
  *S. viridans*group aetiology       -0.88    0.41   0.22-0.76   0.005
                                                                 
  Severe heart failure (Evolution)   1.691    5.42   3.31-8.86   \<0.001
                                                                 
  Neurologic manifestation           0.657    1.93   1.24-2.99   0.001
                                                                 
  Septic shock                       1.445    4.24   2.33-7.70   \<0.001
                                                                 
  Perivalvular extension             0.914    2.49   1.37-4.53   0.003
                                                                 
  Acute renal insufficiency          0.525    1.69   1.09-2.60   0.017
                                                                 
  Surgical treatment                 -0.685   0.50   0.30-0.84   0.010

Discussion
==========

Mortality rate of left-sided IE remains high. Although rates lower than 20% have been reported \[[@B7],[@B22],[@B23]\], they usually range between 20 and 30%\[[@B4],[@B5]\] and are even higher in some subgroups; mortality rates of 50% has been reported in early prosthetic valve IE due to *S. aureus*\[[@B24]\]. Crude mortality rate in our series was 29.5%, an intermediate figure considering the intrinsic features of the patients, the number of complicated cases, and the length of the study period. Considering the evolution of mortality over time, we observed a non-significant upward trend, probably related to an increased percentage of cases caused by more virulent organisms such as *S. aureus*, and to a higher frequency of elderly patients with comorbidities.

Previous studies about the prognosis of IE have often been incomplete in their collection of risk factors, have included heterogeneous subtypes (ie, left-side and right-side endocarditis) or have been carried out on patients treated in a single reference center. Only few multicenter cohort with multivariate analysis studies including large numbers of patients have been reported \[[@B6],[@B7],[@B9],[@B10],[@B13],[@B25]\], of which one included only patients admitted to the ICU \[[@B10]\] and another only patients with prosthetic valve IE \[[@B12]\]. This prospective multicenter study includes cases from both referral and community hospitals. We also include IE in both prosthetic and native valves and we have included most factors found in previous studies, such as patient-related variables, aetiology, and the development of different complications.

A Charlson index of more than 2 points has been reported to be an independent risk factor for mortality in previous studies \[[@B6],[@B9]\]. We used the age-adjusted index on the grounds that age may be related to prognosis \[[@B26]\] and also found it to be related with increased risk of death. Many of our patients had more than one underlying condition. Insulin-dependent diabetes mellitus has been observed to be a risk factor in one study \[[@B27]\] but we did not find such association in ours. On the other hand, a very high mortality rate was found among patients with chronic liver disease (47%), similarly to what has been reported in another Spanish series \[[@B28]\].

Prosthetic valve IE, particularly early episodes and those caused by *S. aureus*, are usually associated with a worse prognosis than native valve IE \[[@B23],[@B29]\]. Crude mortality of prosthetic valve IE in our series was almost 3 times higher than for native IE, corroborating the results of previous studies \[[@B12],[@B29],[@B30]\]. Furthermore, *S. aureus*was independently associated with increased mortality, whilst *Streptoccocus viridans*group was a protective factor. Our results confirm another recent collaborative multicenter study where mortality for IE was higher when due to *S. aureus*(22.4% vs 14.6% for other aetiologies)\[[@B30]\]; association of this microorganism with life-threatening complications, such as septic shock and neurologic manifestations have also been reported \[[@B31]\]. All these data emphasise the prognostic relevance of this microorganism in IE.

Heart failure has been found to be a strong marker for increased mortality in most studies \[[@B8]\]. In contrast to Chu *et al*\[[@B7]\], we did not find heart failure at admission to be associated with a worse prognosis. A possible explanation for this is that heart failure at admission, when due to treatable disorders such as arrhythmia, fluid overload, etc, may be controlled by medical treatment. On the other hand, the development of moderate to severe heart failure during evolution was related to increased mortality. We think that development of heart failure during evolution is probably due in most cases to progressive valve dysfunction, which would only be modifiable by surgery. In fact, surgery was a protective factor in our study. Surgical treatment was a protective factor in only two previous studies \[[@B8],[@B9]\], particularly in complicated cases with severe heart failure \[[@B32]\]. The fact that surgery is an independent protective factor for mortality in our study is possibly related to the high number of complicated cases included with heart failure due to valvular dysfunction. However this date must be interpreted with caution since this is an observational study; in another recent study \[[@B8]\], surgery during episode of IE either was associated with better prognosis when this variable was analysed in a multivariable regression modelling.

The exact impact of surgical treatment in IE is controversial and difficult to assess, since evidence is based in observational studies but not in clinical trials. Some new methods of analysis, such as the use of propensity score, have been applied in some studies in order to improve the control of confounding. However the results of these studies are conflicting probably because of methodological differences, as has been recently reviewed \[[@B33]\].

Neurological complications are frequent and associated with a worse prognosis \[[@B7],[@B10],[@B12]\]. In this study, as found in others, about one quarter of patients developed neurologic complications \[[@B34]\]. We considered this complications only when it was clinically relevant, and not only like alterations in imaging techniques. Embolic phenomena are known to be more frequent at admission and during the first week, to occur despite proper medical treatment, and to be associated with worse prognosis, as was the case in our series.

Septic shock, which was developed by about 10% of our patients, was independently associated with increased mortality. This variable has only been studied previously in a report detailing IE patients admitted to the ICU \[[@B10]\], probably because it is not a frequent complication and cannot be evaluated as an independent risk factor in series with a low number of cases. As septic shock has been associated in general patients with mortality rate of about 50% \[[@B35]\], we consider that this variable helps to identify a high-risk subgroup of patients that may benefit from aggressive management, such as early identification of severe sepsis and triggering evidence-based protocolised care \[[@B36]\].

Vegetations observed in echocardiography have been previously associated to a poor outcome \[[@B8]\] although one study found only large-sized vegetations to be an independent prognostic factor \[[@B6]\]. In our study, a vegetation size of \>20 mm almost reached statistical significance in univariate analysis but did not in multivariate analysis; a limitation of our study is that size of vegetations was not measured in all cases.

Perivalvular extension of infection (abscess and/or fistula) has traditionally been seen as an unfavourable prognostic factor \[[@B7],[@B37]\] although less so in more recent studies \[[@B25],[@B38]\]. As in another recent large study \[[@B7]\] we found this complication to be an independent risk factor for mortality, which may be related to a higher post-surgical mortality associated with the intrinsic technically difficulties of these cases. This is a variable that identify another high-risk subgroup of patients, and must be suspected in presence of risk factors for this complications like prosthetic IE and aortic localization \[[@B25]\].

Our study have some limitations: First, changes in the clinical management of IE may have occurred during the long study period, although the inclusion of this variable in the multivariate model did not affect the results. Second, the majority of cases were included from referral centers so that the percentage of complicated cases may have been overestimated. However, other multicenter studies only include cases from reference centers and, even if represented by a small percentage, our series probably better reflects the overall clinical reality. Third, as TEE was not systematically performed, evaluation of echocardiographic data (size of vegetations, perivalvular extension) may be biased. And fourth, it is an observational study, so some results, such as the protective effect of surgery, must be interpreted cautiously.

Conclusions
===========

We believe that our results may help identify IE patients at increased risk of in-hospital death by using data that are usually bedside available, which identify candidates for a more aggressive management in referral centers, with experience that includes active search for septic and hemodynamic complications and early surgical treatment when indicated.
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